3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
6
Breast
3
Thoracic
1
Sarcoma
1
Other solid neoplasm
1
Other hematologic neoplasm
1
Lymphoid
1
Head & Neck
1
Gastrointestinal
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Ovarian Neoplasms
1
Neoplasms
1
Mesothelioma
1
Lymphoma
1
Leukemia
1
Hematologic Neoplasms
1
Breast Neoplasms
1
Interventions
Cyclophosphamide
4
sargramostim
3
Psychiatric Rehabilitation
3
Paclitaxel
3
Flow Cytometry
3
trametinib
2
pertuzumab
2
pembrolizumab
2
dabrafenib
2
Trastuzumab
2
Specimen Handling
2
Palliative Care
2
Methylprednisolone
2
Melphalan
2
Magnetic Resonance Spectroscopy
2
Immunologic Techniques
2
Filgrastim
2
Biopsy
2
Azacitidine
2
Analgesia
2
Amifostine
2
Alemtuzumab
2
varlilumab
1
ulixertinib
1
trastuzumab biosimilar HLX02
1
tanespimycin
1
stenoparib
1
sapanisertib
1
ruxolitinib
1
rucaparib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Ovarian Neoplasms
×
ribociclib
×
Other hematologic neoplasm
×
Clear all
NCT02187783
2019-07-18
SIGNATURE
Novartis
Phase 2
Completed
106 enrolled
16 charts